The Influence of Milling on the Dissolution Performance of Simvastatin
Open Access
- 17 December 2010
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 2 (4), 419-431
- https://doi.org/10.3390/pharmaceutics2040419
Abstract
Particle size reduction is a simple means to enhance the dissolution rate of poorly water soluble BCS-class II and IV drugs. However, the major drawback of this process is the possible introduction of process induced disorder. Drugs with different molecular arrangements may exhibit altered properties such as solubility and dissolution rate and, therefore, process induced solid state modifications need to be monitored. The aim of this study was two-fold: firstly, to investigate the dissolution rates of milled and unmilled simvastatin; and secondly, to screen for the main milling factors, as well as factor interactions in a dry ball milling process using simvastatin as model drug, and to optimize the milling procedure with regard to the opposing responses particle size and process induced disorder by application of a central composite face centered design. Particle size was assessed by scanning electron microscopy (SEM) and image analysis. Process induced disorder was determined by partial least squares (PLS) regression modeling of respective X-ray powder diffractograms (XRPD) and Raman spectra. Valid and significant quadratic models were built. The investigated milling factors were milling frequency, milling time and ball quantity at a set drug load, out of which milling frequency was found to be the most important factor for particle size as well as process induced disorder. Milling frequency and milling time exhibited an interaction effect on the responses. The optimum milling settings using the maximum number of milling balls (60 balls with 4 mm diameter) was determined to be at a milling frequency of 21 Hz and a milling time of 36 min with a resulting primary particle size of 1.4 μm and a process induced disorder of 6.1% (assessed by Raman spectroscopy) and 8.4% (assessed by XRPD), at a set optimization limit of < 2 μm for particle size and < 10% for process induced disorder. This optimum was tested experimentally and the process induced disorder was determined to be 6.9% (± 2.2) by Raman spectroscopy and 7.8% (± 2.3) by XRPD. Subsequent intrinsic dissolution testing revealed that the process induced disorder was negligible with regard to the dissolution rate. The predicted primary particle size of 1.4 μm could be confirmed experimentally, but due to agglomeration of the primary particles a dissolution rate advantage was not shown, highlighting the importance of dissolution testing at an early stage of drug development.This publication has 11 references indexed in Scilit:
- Effects of Polymorphism and Solid-State Solvation on Solubility and Dissolution RatePublished by Taylor & Francis Ltd ,2018
- Quantification of Process Induced Disorder in Milled Samples Using Different Analytical TechniquesPharmaceutics, 2010
- In-line and real-time process monitoring of a freeze drying process using Raman and NIR spectroscopy as complementary process analytical technology (PAT) toolsJournal of Pharmaceutical Sciences, 2009
- A Discriminatory and Biorelevant Dissolution Test Method for Simvastatin Drug ProductsDissolution Technologies, 2009
- Co-solvent Evaporation Method for Enhancement of Solubility and Dissolution Rate of Poorly Aqueous Soluble Drug Simvastatin: In vitro–In vivo EvaluationAAPS PharmSciTech, 2008
- Relevance of Solid‐state Properties for Pharmaceutical ProductsPublished by Wiley ,2006
- Tablet film-coating with amylose-rich maize starchEuropean Journal of Pharmaceutical Sciences, 2002
- Optimization of a granulation and tabletting process by sequential design and multivariate analysisChemometrics and Intelligent Laboratory Systems, 1998
- Experimental design and optimizationChemometrics and Intelligent Laboratory Systems, 1998
- THE RATE OF SOLUTION OF SOLID SUBSTANCES IN THEIR OWN SOLUTIONS.Journal of the American Chemical Society, 1897